Sona Amin, MD
Endocrinology, Diabetes & Metabolism · Marietta, GANPI 1700958394
Payments from drug & device makers
Across 178 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$463
- Lilly USA, LLC$405
- Abbott$377
- Sanofi-aventis U.S. LLC$247
- Insulet Corporation$234
- Novo Nordisk$196
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,53298%
- Education$100%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 20 | $463 |
| Lilly USA, LLC | 20 | $405 |
| Abbott | 31 | $377 |
| Sanofi-aventis U.S. LLC | 10 | $247 |
| Insulet Corporation | 9 | $234 |
| Novo Nordisk | 9 | $196 |
| Cequr Corporation | 3 | $146 |
| Bayer | 7 | $143 |
| Boehringer Ingelheim | 7 | $127 |
| AbbVie | 7 | $100 |
| Corcept Therapeutics | 3 | $97 |
| Tandem Diabetes Care, Inc. | 5 | $94 |
| Recordati_rare_diseases_inc. | 3 | $85 |
| Sequel Med Tech, LLC | 4 | $84 |
| Amneal Pharmaceuticals LLC | 4 | $80 |
| Mannkind Corporation | 2 | $77 |
| Medtronic(2 entities) | 5 | $75 |
| Valeritas, Inc. | 1 | $65 |
| Radius Health, Inc. | 2 | $64 |
| IBSA Pharma Inc. | 4 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| Dexcom, Inc. | 3 | $43 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Acella Pharmaceuticals, LLC | 2 | $35 |
| AstraZeneca | 2 | $35 |
| Johnson & Johnson | 2 | $26 |
| Amryt Pharma Holdings Ltd | 1 | $26 |
| Change Healthcare Technologies, LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Pfizer | 1 | $18 |
| Theracosbio, LLC | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
| Merck | 1 | $13 |
How this compares
$3,601 in reported general payments places this provider in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 276 | $339,716 |
| MounjaroTirzepatide | 176 | $220,153 |
| JardianceEmpagliflozin | 127 | $185,892 |
| TrulicityDulaglutide | 116 | $168,201 |
| Tresiba Flextouch U-100Insulin Degludec | 100 | $92,597 |
| ProliaDenosumab | 33 | $57,228 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $45,254 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $31,669 |
| FarxigaDapagliflozin Propanediol | 27 | $31,581 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $23,296 |
| Humalog Kwikpen U-100Insulin Lispro | 57 | $22,143 |
| JanuviaSitagliptin Phosphate | 17 | $21,357 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $21,017 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $18,418 |
| InvokanaCanagliflozin | 12 | $16,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $405 | $396,858319 claims |
| Novo NordiskOzempic | $196 | $339,716276 claims |
| Boehringer IngelheimJardiance | $127 | $185,892127 claims |
| AmgenProlia | $463 | $57,22833 claims |
| AstraZenecaFarxiga | $35 | $31,58127 claims |
| MerckJanuvia | $13 | $21,35717 claims |
| Johnson & JohnsonInvokana | $26 | $16,96612 claims |
| AbbVieSynthroid | $100 | $11,690122 claims |
| IBSA Pharma Inc.Tirosint | $62 | $6,09015 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $80 | $3,153327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Marietta
- Miguel MunozMarietta$476K
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.